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Abstract
Background: Induced pluripotent mesenchymal stem cells (iPMSCs) are novel candidates for drug screening,
regenerative medicine, and cell therapy. However, introduction of transcription factor encoding genes for induced
pluripotent stem cell (iPSC) generation which could be used to generate mesenchymal stem cells is accompanied
by the risk of insertional mutations in the target cell genome.
Methods: We demonstrate a novel method using an inactivated viral particle to package and deliver four purified
recombinant Yamanaka transcription factors (Sox2, Oct4, Klf4, and c-Myc) resulting in reprogramming of human
primary fibroblasts. Whole genome bisulfite sequencing was used to analyze genome-wide CpG methylation of
human iPMSCs. Western blot, quantitative PCR, immunofluorescence, and in-vitro differentiation were used to
assess the pluripotency of iPMSCs.
Results: The resulting reprogrammed fibroblasts show high-level expression of stem cell markers. The human
fibroblast-derived iPMSC genome showed gains in DNA methylation in low to medium methylated regions and
concurrent loss of methylation in previously hypermethylated regions. Most of the differentially methylated regions
are close to transcription start sites and many of these genes are pluripotent pathway associated. We found that
DNA methylation of these genes is regulated by the four iPSC transcription factors, which functions as an
epigenetic switch during somatic reprogramming as reported previously. These iPMSCs successfully differentiate
into three embryonic germ layer cells, both in vitro and in vivo. Following multipotency induction in our study, the
delivered transcription factors were degraded, leading to an improved efficiency of subsequent programmed
differentiation.
Conclusion: Recombinant transcription factor based reprogramming and derivatization of iPMSC offers a novel
high-efficiency approach for regenerative medicine from patient-derived cells.
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Background
Induced pluripotent stem cells (iPSCs) are somatic cells
whose characteristics are reprogrammed by ectopic ex-
pression or by introduction of defined transcription fac-
tors to resemble those of embryonic stem cells (ESCs)
[1]. Yamanaka and colleagues [1–4] generated the first
iPSCs using ectopic expression of a series of transcrip-
tion factors, including Oct4, Sox2, Klf4, and c-Myc.
Following their success, many types of mammalian cells
have been successfully induced to the pluripotent state
by related methods. These cells are thought to hold
promise for regenerative medicine, drug screening, disease
modeling, and basic research [1–4]. However, the repro-
gramming mechanism is unclear and some problems re-
main unresolved, including safety issues stemming from
the use of viral vectors, especially in light of the oncogenic
potential of two of the key transcription factors, c-Myc
and Klf4 [5]. Additionally, any insertion of foreign DNA
into the genome poses the risk of insertional mutagenesis.
Integrated vectors are therefore not optimal reprogram-
ming agents due to safety concerns.
In an attempt to circumvent insertional mutagenesis,
significant efforts have been put into the reprogramming
technologies that avoid ectopic DNA integration. Until
now integration-free iPSCs have been derived through ex-
pression of reprogramming factors (RFs) using excisable
(transposon and floxed lentivirus) or nonintegrating vec-
tors (plasmid, episomal, and adenovirus vector) [6–9].
However, iPSCs generated by these approaches either are
left with a short vector DNA after excision or are not en-
tirely free of the risk of transgene insertions [6–9].
One possible way to avoid introducing exogenous gen-
etic modifications to target cells is to deliver the repro-
gramming proteins directly into cells, rather than relying
on the transcription from delivered genes. Zhou et al. [9]
reported the generation of mouse iPSCs using four rounds
of protein transduction of the reprogramming factors
tagged with polyarginine in the presence of VPA. They
found that the transduced proteins appeared to be stable
inside the cells for up to 48 h. This study first demon-
strated that somatic cells could be fully reprogrammed
into pluripotent mesenchymal stem cells (MSCs) by direct
delivery of recombinant reprogramming proteins using a
protein transduction signal peptide. Human iPSC lines
have also been established with protein transductions
without VPA [10]. However, this method is extremely in-
efficient (0.001 %), and slow (8 weeks). This low efficacy
might partially be a result that investigators used whole
cell lysates rather than purified proteins as a source of
transcription factors. Many other groups have now intro-
duced TAT-mediated proteins into mouse and human
somatic cells for reprogramming purposes [11–14].
iPSCs have the ability to undergo self-renewal and
have the potential to differentiate into every cell type of
the human body and represent a potential source of re-
newable cells for cell therapies and regenerative medicine.
Pluripotent stem cells can further give rise to progenitor
cells, such as MSCs that can differentiate into mesodermal
derivatives like bone, fat, cartilage, tendon, and muscle.
Here we have developed a novel recombinant protein
transduction method to generate human iPMSCs from
patient-derived fibroblast using a replication-defective and
persistent Sendai virus (SeVdp) vehicle, Hemagglutinating
Virus of Japan Envelope (HVJ-E). We have delivered four
recombinant purified transcription factors (Oct4, Sox2,
Klf4, and c-Myc) into human fibroblasts and obtained
reprogrammed iPMSCs with higher efficiency than the
methods reported previously. The human iPMSC ge-
nomes were analyzed for DNA methylation changes and
monitored for iPMSC and iPSC specific cell surface
markers. The putative iPMSCs were further differentiated
into osteoblast, adipocyte, pancreatic islet, neural, and
teratoma cells.
Methods
Expression and purification of Oct4, Sox2, c-Myc, and
Klf-4 protein factors
Oct4, Sox2, and c-Myc transcription factors were cloned
into pET28a. Klf-4 was cloned into mammalian expres-
sion vector pcDNA 3.1. Fusion protein constructs in a
pET28a background were transformed into Rosetta DE3
and selected on a LB agar with kanamycin (100 mg/l)
plate at 37 °C overnight. The colonies were inoculated in
100 ml of LB-kanamycin and grown at 37 °C overnight.
For expression, 10 ml of the overnight culture was inoc-
ulated into 1 l LB-kanamycin at 37 °C for 2–3 h until
OD600 reached 0.6–0.8. IPTG was added to a final con-
centration of 0.5 mM, and the culture was incubated for
another 16 h at 18 °C. Cells were harvested and stored
at –20 °C. Unless otherwise indicated, all subsequent
steps were performed at 4 °C. The cell pellet was sus-
pended at 1:20 dilution on ice in buffer containing 20
mM Tris–Cl pH 8.5, 1 M NaCl, 1 mM EDTA, 0.1 mM
PMSF, and 5 % glycerol. This suspension was sonicated
at ~36 W, at 40-min intervals for 3 min until >90 % of
the cells were broken. The cell lysate was centrifuged for
30 min at 8000 rpm to sediment cellular debris. The
pellet was suspended at 1:20 dilution on ice in buffer
containing 20 mM Tris–Cl, pH 8.5, 1 M NaCl, 8 M urea,
20 mM β-ME, and 20 mM imidazole at room
temperature and gently stirred overnight. The suspended
pellet was centrifuged at 18,000 rpm for 1 h at 12 °C
and supernatant collected. The supernatant was loaded
onto a 5-ml nickel column under denaturing conditions
(buffer A: 20 mM Tris–Cl, pH 8.5, 1 M NaCl, 8 M urea,
and 20 mM imidazole). Unbounded protein was washed
with 20 column volumes of buffer A, and the bound
protein was eluted with buffer B (20 mM Tris–Cl, pH
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8.5, 1 M NaCl, 8 M urea, and 500 mM imidazole). DTT
was added to the elution fractions to a final concentration
of 5 mM followed by gentle stirring at 4 °C for 2–4 h.
For Klf-4 purification, pcDNA3.1-Klf-4 construct was
transfected into FreeStyle™ 293-F cells in a spinner flask
and cells were incubated on an orbital shaker platform
at 125 rpm in a 37 °C incubator with humidity and 8 %
CO2 for 48 h. Then 200 ml of transfected 293F cells
were harvested and resuspended in 200 ml lysis buffer
(50 mM Tris–Cl, pH 7.3, 150 mM NaCl, 1 % CA-630,
aprotinin 1 μg/ml, leupetin 1 μg/ml, pepstatin 1 μg/ml,
bestatin 1 μM, and 1 mM PMSF) and shaken on ice for
30 min. The cell lysate was centrifuged for 40 min at
14,000 rpm to sediment cellular debris. The supernatant
was filtered through a 0.22 μM membrane and loaded
onto a 5-ml DEAE column and the flow through was
collected. This flow-through protein solution was loaded
onto a 1-ml nickel column, washed with 40 mM imid-
azole and then eluted by elution buffer (50 mM Tris–Cl,
pH 7.3, 150 mM NaCl, and 250 mM imidazole) with 50
column volumes in a 0–100 % gradient. Purified Klf4
was dialyzed into the storage buffer (20 mM Tris–Cl pH
8, 1 mM DTT, 100 mM NaCl, and 50 % glycerol) and
stored at –80 °C.
Refolding of proteins and protein binding assay
The denatured Oct4, Sox2, and c-Myc eluate was
diluted ~10-fold into pre-cooled refolding buffer (50 mM
Tris–Cl, pH 8.5, 500 mM NaCl, 500 mM Arg, 0.1 %
PEG4000, 0.1 mM EDTA, 1 mM GSH, and 0.1 mM GSSH)
with gentle stirring to a final concentration of proteins be-
tween 0.05 and 0.1 mg/ml and was incubated at 4 °C for 48
h. The refolded protein was dialyzed against continuous ex-
change of fresh dialysis buffer (1 × PBS buffer, 5 mM β-ME,
and 5 % glycerol) at 4 °C for 64 h. Refolded proteins were
loaded onto a 1-ml nickel column and the target protein
eluted with 100 % buffer B (buffer A: 1 × PBS buffer, 5 mM
β-ME, 5 % glycerol, and 10 mM imidazole; buffer B:
1 × PBS buffer, 5 mM β-ME, 5 % glycerol, and 500 mM
imidazole) in a 50 ml gradient. The refolded proteins were
dialyzed against the storage buffer (1 × PBS buffer, 5 mM
DTT, and 50 % glycerol) and stored at –80 °C. Oct4, Sox2,
c-Myc, and Klf-4 were further tested for exonuclease,
endonuclease, and endotoxin presence. DNA-binding ac-
tivity of these protein factors was tested with electrophor-
etic mobility shift assays (EMSAs) using oligonucleotide




TGACCTGAAGGCAGAGTCAG; and Klf-4, CTGAC
TCTGCCTTCAGGTCACCCTATTAAGTCTCGAG.
The linear DNA fragments (100 nM) were incubated at
95 °C for 5 min in 1 × annealing buffer (10 mM Tris–Cl,
pH 8.0, 50 mM NaCl, and 1 mM EDTA) and gradually
cooled down to room temperature for annealing. For
DNA binding reaction, 10 nM of the annealed oligonucle-
otides were incubated with the target proteins (2 μg) in 20
μl binding buffer (10 mM Hepes, pH 7.8, 5 mM MgCl2,
50 mM KCl, 0.5 mM DTT, and 1 % glycerol) at 26 °C for
1 h. Electrophoretic mobility assay was performed by
adding 2 μl of 10 × gel loading dye (50 % glycerol and
10 % SYBR green dye) to the DNA protein mixture and
10 μl of each sample was analyzed using a native
polyacrylamide gel (4 % acrylamide, 2.5 % glycerol, and
0.5 × TBE). The samples were resolved at 4 °C.
Generation of putative induced stem cells using HVJ
envelope
The HVJ envelope (HVJ-E) transfection kit (GenomONE™)
was purchased from Cosmo Bio Co., Ltd. Inactivation of
HVJ has been confirmed for each lot by the viral proli-
ferative potential rule-out test, using cultured cells and
fertilized chicken eggs. Human fibroblasts were seeded at
2 × 105 cells per well in normal culture media (DMEM
supplemented with 10 % FBS). On the next day, media
were changed to fresh media supplemented with the
HVJ-E transduction complex. After overnight culture, the
protein transduction media were replaced by normal cul-
ture media, and cells were cultured for an additional 48 h
before repeating the same protein transduction cycle.
After three rounds of protein transduction, cells were pas-
saged onto VTN-coated dishes at day 10 in iPSC culture
media (Essential 8™ Medium; Invitrogen). Media were
changed every 3–4 days and cultured for another 20 days
(Fig. 1b).
Localization of transfected reprogramming proteins
To determine the intracellular localization of transcrip-
tion factors, protein-transduced cells were immuno-
stained and examined by fluorescent microscopy. Cells
were harvested 24, 48, 72 and 96 h post transduction,
washed with PBS, and fixed in 4 % (v/v) formaldehyde in
PBS at room temperature for 1 min. Cells were incu-
bated with the diluted primary anti-his tag antibody
(Novagen) at 1:1000 dilution at room temperature for 1
h. After washing three times with PBS, fluorescence-
conjugated secondary antibody (anti-mouse IgG (H + L)
Alexa Fluor® 488 Conjugate; CST) at 1:1000 dilution was
added and incubated for 1 h at room temperature in the
dark. Cells were again washed with PBS and nuclear
DNA was stained by 1:3000 diluted Hoechst 33342 stain
(Sigma-Aldrich). Images were captured by Olympus
DP70 microscope.
Surface antigen analysis of putative induced stem cells
Cell surface antigens for human iPSCs were analyzed
with FACS. Cells (1 × 105 cells per well) were incubated
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with one of the following primary antibodies: anti-CD24
antibody (Abcam), 1:100 dilution; anti-SSEA3 antibody
(Abcam), 1:100 dilution; anti-CD105 antibody (Abcam),
1:200 dilution; anti-Nanog antibody (CST), 1:100 dilu-
tion; anti-Sox2 antibody (CST), 1:300 dilution; and anti-
Oct4 antibody, 1:600 dilution (CST). After 1 h of incuba-
tion at 4 °C, the cells were washed, centrifuged, stained
with 100 μl of a secondary antibody selected from anti-
mouse IgG (H + L) Alexa Fluor® 488 Conjugate (CST) at
1:1000 dilution, anti-rat IgG (H + L) Alexa Fluor® 488
Conjugate (CST) at 1:1000 dilution, and anti-rabbit IgG
(H + L) Alexa Fluor® 488 Conjugate (CST) at 1:1000 dilu-
tion. The stained cell pellets were suspended in 200 μl
PBS/10 % FCS at 4 °C for flow cytometry analysis. All anti-
bodies were validated for antigen specificity.
Immunofluorescence assays of putative induced stem
cells and quantitative PCR
ALP staining was performed using the Alkaline Phos-
phatase Detection Kit (Millipore) as instructed by the
manufacturer. Immunocytochemistry was performed
using standard protocols. Briefly, cells were fixed using 4
% paraformaldehyde (PFA; Sigma-Aldrich), washed three
times with PBS, and then incubated in PBS containing 0.3
% TritonX-100 (Sigma-Aldrich) and 5 % BSA for 1 h at
room temperature. The cells were then incubated with
primary antibody at 4 °C overnight: anti-CD24 antibody
(Abcam), 1:100 dilution; anti-SSEA3 antibody (Abcam),
1:100 dilution; anti-CD105 antibody (Abcam), 1:200 dilu-
tion; anti-Tra1-60 (Millipore), 1:200 dilution; anti-Tra1-81
(Millipore), 1:200 dilution; anti-Nanog antibody (CST),
1:100 dilution; anti-Sox2 antibody (CST), 1:300 dilution;
and anti-Oct4 antibody (CST), 1:600 dilution.
After washing three times with PBS, cells were incu-
bated with secondary antibodies: anti-mouse IgG (H + L)
Alexa Fluor® 488 conjugate (CST), 1:1000 dilution; anti-
rat IgG (H + L) Alexa Fluor® 488 conjugate (CST),
1:1000 dilution; and anti-rabbit IgG (H + L) Alexa Fluor®
488 conjugate (CST), 1:1000 dilution. Nuclei were
detected by Hoechst 33342 (Sigma-Aldrich) staining.
Images were captured using an Olympus DP70 digital
camera. Isotype controls are shown in Additional file 1:
Figure S1.
Total RNA was extracted using TRIZol® Reagent (Life
Technologies) followed by cDNA synthesis using M-MuLV
Reverse Transcriptase and Oligo (dT)23VN (NEB). Quanti-
tative PCR (qPCR) was performed with iTaq™ Universal
SYBR® Green Supermix (Bio-Rad) using the primers pre-
sented in Table 1 and RT-PCR was performed for gene ex-
pression studies using the primers presented in Table 2. All
antibodies were validated for antigen specificity.
Whole genome bisulfite sequencing and bioinformatics
analysis
Genomic DNA was extracted from 5000 CD24+ or fibro-
blast cells using the SDS/Proteinase K/Phenol chloroform
method [15]. Then 20 pg of unmethylated lambda DNA
was spiked into 20 ng of iPMSC genomic DNA. The
combined DNA was sheared to 200 bp fragments using a
Covaris sonicator. Fragmented DNAs were end-repaired,
dA-tailed, and ligated to a methylated NEB Illumina
adaptor using the NEBNext® Ultra™ DNA Library Prep Kit
Fig. 1 Characterization of recombinant Yamanaka transcription factors for transduction. a Recombinant refolded and purified Oct4, Sox2, c-Myc,
and Klf4 were analyzed using denaturing Bis-Tris NuPage gel. Marker protein standards are shown in lane 1. b Schematic protocol depicting the
process and timeline for generating iPMSCs. c Protein transduction and visualization in human fibroblasts 24, 48, 72, and 96 h post HVJ-E transduction
of cells. Cells were stained with Hochest 33342 dye for nuclei (blue), and immunostained with anti-His antibody (green) for localization of
the recombinant Yamanaka transcription factors. Merged images are shown for 24, 48, 72 and 96 h post transduction. d day, IPSC induced pluripotent
stem cell
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for Illumina (E7370S; NEB). Adaptor ligated DNA was
bisulfite converted using the EZ DNA Methylation Kit
(Zymo Research). Libraries were enriched by PCR using a
mutated version of Q5 polymerase that can read DNA
templates containing dU (New England Biolabs) and se-
quenced on the Illumina NextSeq 500 platform with 150
bp paired-end reads. Libraries were made in duplicate.
Two high-output runs were carried out.
Adaptor trimmed sequencing reads were mapped to
hg19 and bacterial phage lambda genomic sequences and
CpG methylation levels were extracted using Bismark
[16]. CpG sites with at least two reads covered in two rep-
licate libraries were included in the downstream analysis.
CpG methylation levels in genomic regions were obtained
by the local likelihood smoothing function in the bsseq R
package [17]. Differential methylation between CD24+ and
fibroblast cells was analyzed using t statistics. Regions
with a mean differential methylation level higher than
0.1 were defined as differentially methylated regions
(DMRs).
DMRs were annotated to the UCSC RefGene table,
and their distribution in genomic elements including
promoter, 5′ UTR, exon, intron, intergenic, 3′ UTR,
TTS, and repetitive sequences was calculated using
HOMER [18]. Fold enrichment of DMRs in specific gen-
omic elements and the distance of DMRs to their closest
TSS were also calculated using HOMER. Then 60,000
genomic regions, each with a length of 200 bp, were ran-
domly sampled three times from the human genome
hg19, and these three random datasets were used as
controls when analyzing the distance of DMRs to TSS.
Genes harboring at least one DMR (DMR genes)
within the ±2 kb region of TSS were used for gene-set
enrichment analysis, since DNA methylation changes
located in the TSS or flanking regions are more likely to
affect gene expression. A total of 866 genes were investi-
gated for enrichment within the MSigDB database (gene set
CGP: chemical and genetic perturbations) using a hyper-
geometric distribution model and p values were corrected
to FDR (q value) with the Benjamini-Hochberg method
[19]. Interaction networks of genes enriched in each gene
set were constructed using GeneMANIA [20].
Directed in-vitro differentiation
The pluripotency of stem cells was examined by di-
rected in-vitro differentiation. For adipogenic differen-
tiation (mesoderm), stem cells were induced in the
medium (10 % FBS/DMEM, 500 μM IBMX, 1 μM dexa-
methasone, 10 μg/ml insulin, and 200 μM indomethacin)
for 3 weeks, with media changed every third day. For osteo-
genic differentiation (mesoderm), iPMSCs were induced in
the medium (10 % FBS/DMEM, 50 μM L-ascorbic acid, 10
mM β-glycerophosphate, and 0.1 μM dexamethasone) for 2
weeks, with media changed every third day. For neurogenic
differentiation (ectoderm), iPMSCs were first preincubated
in 20 % FBS/DMEM, 1 mM β-mercaptoethanol (BME),
and 10 ng/ml basic fibroblast growth factor (bFGF; Invi-
trogen) for 24 h, and then induced in 2 μM valproic acid,
10 μM forskolin, 1 μM hydrocortisone, and 5 μg/ml insu-
lin for 1 week, with media changed every third day. For
pancreatic islet differentiation [21–23]: day 1, RPMI (with-
out FBS), activin A (100 ng/ml), and Wnt3a (25 ng/ml);
days 2–3, RPMI with 0.2 % vol/vol FBS and activin A (100
ng/ml); days 4–6, RPMI with 2 % vol/vol FBS and FGF-10
(50 ng/ml); days 7–9, DMEM with 1 % vol/vol B27 sup-
plement, cyclopamine (0.25 μM), all-trans retinoic acid
(RA, 2 μM), and Noggin (50 ng/ml); and days 10–12,
DMEM with 1 % vol/vol B27 supplement.
Table 1 Primers for quantitative PCR reactions
Gene
name














Table 2 Primers for RT-PCR reactions
Gene
name
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Immunofluorescence assay, PCR, and western blotting of
differentiated iPMSCs
Induced osteogenic cells were fixed by 4 % paraformal-
dehyde (Sigma-Aldrich) and stained by anti-osteocalcin
antibody (1:200 dilution; Santa Cruz); induced neuro-
genic cells were stained with anti-GFAP antibody (1:300
dilution; CST), anti-Nestin antibody (1:300 dilution;
CST), anti-MAP2 antibody (1:200 dilution; Abcam), and
anti-β-Tubulin III (1:200 dilution; Abcam); and induced
pancreatic islet cells were stained with anti-Pdx1 antibody
(1:400 dilution; CST), anti-glucagon antibody (1:400 dilu-
tion; CST), and anti-insulin antibody (1:400 dilution, 3014;
CST) respectively. Total RNA was extracted using TRIZol®
Reagent (Life Technologies) followed by cDNA synthesis
using M-MuLV Reverse Transcriptase and Oligo
(dT)23VN (NEB). qPCR was performed with iTaq™ Uni-
versal SYBR® Green Supermix (Bio Rad). Western blotting
was performed for osteocalcin, microtubule-associated
protein 2 (MAP2), β-Tubulin III, ADFP, and Plascidin L.
All antibodies were validated for antigen specificity.
Glucose-stimulated insulin secretion assay
To determine whether cells could respond to glucose in
vitro [24], the differentiated cells were preincubated for
4 h at 37 °C in Krebs–Ringer bicarbonate HEPES
(KRBH) buffer of the following composition: 129 mM
NaCl, 5 mM NaHCO3, 4.8 mM KCl, 1.2 mM KH2PO4,
1.2 mM MgSO4, 2.5 mM CaCl2, 10 mM HEPES, and 0.1
% (wt/vol) BSA at pH 7.4.
For high glucose-induced insulin release, cells were in-
cubated in KRBH buffer supplemented with different
concentrations of glucose (3.3 mM and 16.7 mM) to-
gether with 10 μM tolbutamide (Sigma) for 2 h at 37 °C.
The concentration of insulin secreted into the culture
media was measured using a human insulin enzyme-
linked immunosorbent assay (ELISA) kit (CSB-E05069h;
CUSABIO).
Directed in-vivo differentiation on scaffold
Adipogenic iPMSCs and polyglycolic (PGA) fibro scaffold
contracts were implanted subcutaneously on the backs of
nude mice. Osteogenic iPMSCs and porous β-tricalcium
phosphate (β-TCP) scaffold contracts were also implanted
subcutaneously on the backs of nude mice. Eight weeks
after implantation animals were sacrificed, and the cell
scaffold constructs were harvested and fixed in freshly
prepared 4 % paraformaldehyde in PBS.
Histochemistry and immunohistochemistry assay
Following paraformaldehyde fixation, the scaffolds were
embedded in paraffin. Ten micron tissue sections were cut
using RM2235 radial microtomes (Leica Microsystems) for
histological analysis and stained with hematoxylin and
eosin (H & E). In the osteogenic group, tissue sections were
also stained by a modified Masson Trichrome [25] and
Von Kussa [26] staining. Five mice from each group were
analyzed. Immunohistochemistry staining of HLA-ABC
(CST) at 1:1000 dilution were used to detect whether the
tissue formed in vivo originated from human iPMSCs. Sec-
tions were observed under an AX80 microscope (Olympus,
Tokyo, Japan).
Teratoma formation
Reprogrammed iPMSC suspensions (1 × 107) were mixed
with matrigel (BD Bioscience) and injected subcutane-
ously into NOD/SCID mice without anesthesia. After 2
months teratomas were collected and fixed in 4 %
paraformaldehyde in PBS, embedded in paraffin, and
sectioned at 10 μm using RM2235 radial microtomes
(Leica Microsystems). Sections were subjected to histo-
logic staining with H & E and immunohistochemistry
staining of HLA-ABC as already described and observed
under an AX80 microscope (Olympus).
Results
Generation and localization of transfected proteins
The purified Oct4, Sox2, c-Myc, and Klf4 were used for
HVJ-E packaging (Fig. 1a, b). To determine the intracel-
lular localization of transduced transcription factors by
HVJ-E, we used anti-His tag antibody and visualized the
localization of these His-tagged protein factors using a
microscope. Indeed, 24 h after viral transduction, 90 %
of the living cells were positive for His-tag transcription
factors and they all localized in the nucleus, suggesting
that the transcription factors are indeed transported
across the nuclear membrane (Fig. 1c). Fluorescence in-
tensity decreased significantly 96 h post transduction,
accounting only for about 5 % fluorescent fibroblasts,
suggesting a gradual degradation of the His-tagged tran-
scription factors. Therefore we concluded that HVJ-E is
an efficient vehicle for protein transduction into fibro-
blasts, and recombinant transcription factors remain in
the nucleus for at least 72 h (Fig. 1c).
Generation and validation of reprogrammed stem cells
To generate iPSCs from human fibroblasts, the fibro-
blasts were subjected to three protein transduction cy-
cles at 72-h intervals (Fig. 1b), as described in Methods.
On day 10, the cells were gently dissociated and trans-
ferred into VTN-coated 10-cm dishes and cultured until
stem cell-like colonies appeared (around day 30). The
cells lost their characteristic fibroblast morphology and
formed tight, round colonies, with enlarged nuclei and a
high nucleus-to-cytoplasm ratio. To verify the undiffer-
entiated state of the generated putative stem cells, we
first assayed alkaline phosphatase (ALP) activity. All
colonies exhibited positive staining for ALP. Among the
reprogrammed fibroblasts that did not form colonies,
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about 60 % tested were positive for ALP (ALP1 and
ALP2; Fig. 2a). To further evaluate the undifferentiated
state we performed immuncytochemical staining for the
major pluripotency markers Sox2, Oct4, Nanog, Tra1-60,
Tra1-81, SSEA-3, CD105, Lin28, and CD24 (Fig. 2b). This
staining confirmed uniform expression of these pluripo-
tency markers in all colonies. Based on ALP staining and
immuncytochemical staining for the major pluripotency
markers, the reprogramming efficiency was about ~30 %.
To establish stable iPSC lines, colonies were seeded on
VTN-coated plates and cultured in Essential 8™ medium.
Over 7 days of culture, these colonies did not grow, but
did differentiate into fibroblast-shaped cells suggesting
iPMSCs. Cells additionally stained positive for pluripo-
tency markers CD105, CD90, CD24, and Sox2. We also
performed flow cytometry analysis of the whole popula-
tion of reprogrammed fibroblasts utilizing an extended
set of pluripotency markers, namely Nanog, Oct4, Sox2,
SSEA-3, CD24, and CD105. Approximately 80 % of the
cells were positive for Nanog, Oct4, Sox2, and SSEA-3,
and about 50 % of the cells were positive for CD24 and
CD105 (Fig. 2c). The relative expression of the
pluripotency marker genes was determined for the
reprogrammed fibroblast population using qPCR, with
housekeeping gene GAPDH as a reference. The fibro-
blast population was treated with three protein trans-
duction cycles at 72-h intervals and contained a mixed
population of reprogrammed cells and fibroblasts. The en-
dogenous pluripotency marker expression levels increased
significantly, except ABCG2, compared with fibroblasts
(Fig. 2d, Table 1), suggesting the reprogrammed stem cells
display all features specific to iPMSC cells, specifically
morphology and pluripotency marker expression.
Epigenome reprogramming of the iPMSCs derived from
human fibroblasts
DNA methylation change, especially CpG methylation, is
an important epigenetic mark affecting gene expression
during the reprogramming process. To help explain
expression changes in pluripotency-related genes after
introduction of recombinant Yamanaka factors into
fibroblasts, and to investigate the epigenetic mechanisms
underlying reprogramming, we performed whole gen-
ome bisulfite sequencing on the CD24+ iPMSCs and cor-
responding control fibroblast cells.
Fig. 2 Generation of iPMSCs by HVJ-E transduced purified recombinant transcription factors. a ALP staining of putative iPMSCs. Control fibroblasts
were without reprogramming and stained with ALP. ALP1 denotes expanded cells with ALP staining. The expanded iPMSCs grew in compact colonies and
stained positive for ALP (ALP2). b Putative clone expressing hESC markers (green), including Sox2, Oct4, Nanog, Lin28, Tra1-60, Tra1-81,SSEA-3, and CD24.
Nuclei were stained with Hochest 33342 stain (blue) and the images were merged. Scale bars = 50 nM. c FACS analysis of the colonies differentiated into
fibroblast-shaped cells demonstrating expression of pluripotent stem cell markers including CD105, CD24, and Sox2 (left). Surface antigen profiling of
the whole population of protein-reprogrammed fibroblasts for Nanog, Oct4, and SSEA-3 is also shown (right). d Endogenous pluripotency markers of
RNA expression in the reprogrammed fibroblasts determined by qPCR. GAPDH was used for normalization. Note that total RNA was extracted from a
mixed population of cells with ~30 % displaying stem cell characteristics. *p < 0.01 between control fibroblasts before and after reprogramming using
the protein factors. IPMSC induced pluripotent mesenchymal stem cell
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A total number of 310 million WGBS reads from the
CD24+ libraries were mapped to hg19 and 370 million
reads from the fibroblast libraries were mapped, repre-
senting about 10× genome coverage for each individual
library. Approximately 44 million CpG sites were cov-
ered by each library, estimated to be 78.6 % of all CpG
sites in the human genome. Also, using lambda DNA
spike-in controls, we calculated that the bisulfite conver-
sion rate of each library was greater than 99 %.
We analyzed the differential methylation between
CD24+ and fibroblast cells using a smoothing coupled
t-statistics approach. By setting a differential methylation
threshold of 0.1 (10 %), 29,584 hypomethylated DMRs and
31,316 hypermethylated DMRs were identified (Fig. 3a).
While the numerical distribution of CpG sites in each
DMR and the length of DMRs are similar between the
hypomethylated and hypermethylated groups (Additional
file 2: Figure S2A, B), there is a difference in the distribu-
tion of DMRs across CpG methylation levels. Specifically,
we found that the gain of methylation (hypermethylated
DMRs) occurs in regions with low-to-medium extents of
methylation, while the loss of methylation (hypomethy-
lated DMRs) occurs in regions that were originally highly
methylated (Fig. 3b).
Genomic annotation revealed that DMRs were enriched
in functional elements (i.e., promoter, 5′ UTR, exon, 3′
UTR, and TTS), most especially in promoter regions
(highest log2-fold enrichment, Fig. 3c), but depleted in
intergenic regions, which play a less functional role in
gene expression (Fig. 3c). No apparent DMR enrichment
was found in repetitive elements (data not shown). Since
DMRs are mostly enriched in promoter regions, we ana-
lyzed the distribution of the distances of each DMR to its
closest TSS. Remarkably, distance density plots demon-
strated that both hypermethylated and hypomethylated re-
gions extend from TSS ± 1 kb regions with a bi-peak
distribution pattern and are depleted at TSS sites, but not
at three random region controls (Fig. 3d and Additional
file 2: Figure S2C, D), indicating that introduction of the
four recombinant transcription factors leads to changes in
Fig. 3 WGBS revealed CpG methylation alterations in iPMSCs compared with fibroblast cells. a Volcano plot depicting the DMRs in iPMSCs
compared with fibroblasts (Fib), with the horizontal axis representing methylation differences and the vertical axis representing the standard
deviation (sd) in t statistics. b Box plot showing the distribution of CpG sites based on different methylation levels. c Bar plot showing the
enrichment of DMRs in different genomic features. d Distribution of DMR distances to its closest TSS; controls are generated by randomly
sampling 60,000 regions of 200 bp from hg19
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the DNA methylation patterns of promoter regions, pos-
sibly correlated with gene expression. The depletion of a
DMR at its TSS, however, could be due to the occupancy
of H3K4me3 and H2A.Z histone variants at the TSS,
which are strongly antagonistic to DNA methyltransferase
targeting (DNMT) and thus keep TSS persistently hypo-
methylated [27].
A functional study was carried out using genes with at
least one DMR in their promoter region. Gene set en-
richment analysis revealed that DMR genes are highly
enriched in stem cell-related categories (Table 3). Be-
sides enrichment in general stem cell genes, genes with
DMR were also observed in sets that are regulated by
stem cell-related transcription factors (KLF1, MAPK8,
NANOG, SUZ12, SOX2, and MYC). These enrichment
results indicate that the transduced recombinant tran-
scription factors regulate the programmed DNA methy-
lation of stem cell-related genes.
To further understand the mechanism of DNA methy-
lation changes exerted by Yamanaka transcription fac-
tors, we constructed gene interaction networks using the
DMR genes enriched in specific categories (Table 3). In-
deed, enriched genes could be readily organized into
networks, and Yamanaka transcription factors showed
extensive interaction relationships with enriched gene
nodes, indicating a legitimate relationship between al-
tered DNA methylation and introduction of Yamanaka
transcription factors (Additional file 3: Figure S3).
An overlapping analysis of enriched DMR genes in dif-
ferent gene sets revealed that FEZ1 and OLFML3 were
found in STEM_CELL_UP, NANOG_TARGETS, and
SOX2_TARGETS sets. FEZ1 is essential for normal
axonal bundling and elongation within axon bundles
and OLFML3 plays an essential role in dorsoventral pat-
terning during early development. The DNA methyla-
tion change in these genes is also consistent with the
gain of pluripotency following transduction of Yamanaka
transcription factors into human fibroblasts (Additional
file 4: Figure S4).
In-vitro differentiation of iPMSCs
The main feature of the stem cell is its inherent property
to differentiate into different cell types. Characteristic
stem cell properties can be assayed both in vitro and in
vivo. In-vitro differentiation assays were performed to as-
sess the developmental potential of the iPMSCs derived
by protein factors. iPMSCs were induced into adipocytes
in medium containing 1 μM dexamethasone, 200 μM
indomethacin, 500 μM IBMX, and 10 μg/ml insulin for 2
weeks. Oil Red droplets were observed in >50 % of the
iPMSCs, demonstrating an efficient differentiation process
of the cells (Fig. 4a). The mRNA expression of important
transcription factors involved in adipogenesis, such as
PPARγ and C/EBPα, was also significantly increased by
RT-PCR (Fig. 4b) and qPCR assay between fibroblast-
derived control iPMSCs and adipogenic iPMSCs (Fig. 4c).
We also analyzed the osteogenic differentiation potential
of the iPMSCs. After being induced into osteoblasts with
50 μM L-ascorbic acid, 10 mM β-glycerophosphate, and
0.1 μM dexamethasone for 2 weeks, the cells were stained
for osteocalcin and Hoechst 33342. Indeed, osteocalcin
was deposited throughout except in the nucleus (Fig. 4d).
Furthermore, Alizarin Red staining displayed calcium
nodules secreted by induced osteoblasts in 90 % of the
cells (Fig. 4e). We also performed RT-PCR analysis to de-
termine gene expression for collagen I, cbfa1, osteocalcin,
osterix, BSP, and osteonectin. Indeed, only osteogenic-
specific genes cbfa1, osterix, and osteonectin were found
to be overexpressed following differentiation compared
with parental iPMSCs (Fig. 4f).
Similarly, neural differentiation iPMSCs were replanted
on a poly-D-lysin/laminin-coated surface and first induced
Table 3 Gene set enrichment analysis of genes with at least one DMR in the promoter
Gene set name Number of genes





PILON_KLF1_TARGETS_DN 1972 107 0.0543 2.01 × 10–19
YOSHIMURA_MAPK8_TARGETS_UP 1305 73 0.0559 5.87 × 10–14
BOQUEST_STEM_CELL_UP 260 31 0.1192 1.14 × 10–13
BENPORATH_NANOG_TARGETS 988 61 0.0617 1.70 × 10–13
LIM_MAMMARY_STEM_CELL_UP 489 40 0.0818 1.73 × 10–12
WONG_ADULT_TISSUE_STEM_MODULE 721 46 0.0638 9.24 × 10–11
PASINI_SUZ12_TARGETS_DN 315 28 0.0889 9.54 × 10–10
BENPORATH_SOX2_TARGETS 734 43 0.0586 4.40 × 10–9
BENPORATH_ES_WITH_H3K27ME3 1118 53 0.0474 5.27 × 10–8
ZHANG_TLX_TARGETS_60HR_UP 293 24 0.0819 9.01 × 10–8
DANG_BOUND_BY_MYC 1103 51 0.0462 2.09 × 10–7
DMR differentially methylated region
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in DMEM culture medium containing 20 % FBS, 1 mM
BME, and 10 ng/ml bFGF for 24 h. Media were then
changed to DMEM containing 10 % FBS supplemented
with 5 mM KCl, 2 μM VPA, 10 μM forskolin, 1 μM
hydrocortisone, and 5 μg/ml insulin and cultures were
maintained for 14 days. Seven days after induction, cells
started to develop a neuronal morphology, namely neural
cells with neuraxon and dendrites were observed by light
microscopy. The cells were additionally positive for nestin
(a neural progenitor cell (NPC) marker), for glial fibrillary
acidic protein (GFAP; an intermediate filament (IF) protein
that is expressed by numerous cell types of the central ner-
vous system (CNS)), for MAP2 (a neuron-specific cytoskel-
etal protein), and for neural class III β-Tubulin (β-Tubulin
III; a neuron marker) (Fig. 5a). These observations demon-
strated that iPMSCs were able to generate NPCs and
differentiate further into mature neurons. RT-PCR ana-
lysis detected nestin and GFAP expression at the early
stages of NPC formation (Fig. 5b), followed by MAP2 and
β-Tubulin III expression as cells differentiated further into
mature neurons 14 days post induction (Fig. 5c).
In yet another example, iPMSCs were induced into
islet cells over a 12-day period. After induction, typical
endocrine aggregates were formed. Immunofluorescent
staining showed that the cell clusters were positive for
insulin. It has been reported that the immunoreactivity
of insulin in the cell clusters might be due to the uptake
of insulin from the media. To distinguish this possibility
and to characterize pancreatic differentiation in detail,
immunofluorescent staining of pancreatic endocrine
hormones was performed, including glucagon, which is
synthesized and secreted from alpha cells of the islets
(Fig. 5d). Pancreatic and duodenal homeobox 1 (Pdx1), a
transcription factor necessary for pancreatic develop-
ment and β-cell maturation, also stained positively in in-
duced iPMSCs (Fig. 5d). The gene expression profile
analyzed by qPCR further confirmed the pancreatic dif-
ferentiation of iPMSCs, as the relative gene expression
levels of insulin, glucagon, and Pdx1 were significantly
increased compared with the original control fibroblast-
derived iPMSCs (Fig. 5e). To determine whether the
differentiated iPMSCs were responsive to glucose chal-
lenge, insulin release after exposure to high glucose was
measured using a human insulin ELISA kit. Insulin secre-
tion after cells were exposed to high concentrations of glu-
cose (16.7 mM) increased significantly compared with
cells exposed to low concentrations of glucose (3.3 mM),
as well as KRBH buffer without glucose (Fig. 5f).
Fig. 4 In-vitro adipogenic and osteogenic differentiation potential of induced stem cells. a iPMSCs were induced into adipocytes in defined medium
and lipid droplets were subsequently stained by Oil Red O. b mRNA expression levels of PPARγ and C/EBPα marker genes in the adipogenic group
using RT-PCR and resolving the amplicon on agarose gel. c Expression levels of PPARγ and C/EBPα compared with control group using qPCR. Note
that total RNA was extracted from mixed population of cells with ~30 % displaying stem cell characteristics. *p < 0.01 between control IPMSCs before
differentiation (fibroblasts) and after adipogenic conversion (adipogenic IPMSCs). d iPMSCs were induced into osteoblasts and subsequently stained for
osteocalcin. e Alizarin Red staining identified the calcium nodules secreted by induced osteoblasts. f Osteoblast specific gene expression in iPMSCs
and the osteogenic group by RT-PCR and subsequently resolving the amplicon on agarose gel. IPMSC induced pluripotent mesenchymal stem cell
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In-vivo differentiation of iPMSCs
To establish the ability of iPMSCs to differentiate in
vivo, reprogrammed fibroblasts were seeded on a
porous β-TCP (Fig. 6a) scaffold and cultured in the
osteogenic induction medium for 3 weeks. β-TCP
showed high biocompatibility for induced fibroblasts
as indicated by cell adherence and proliferation on
the porous β-TCP scaffold (Fig. 6b). After 3 weeks,
β-TCP scaffold constructs were implanted subcutane-
ously on the backs of nude mice. Two months after
implantation the animals were sacrificed, the scaf-
folds harvested, and histological analysis was per-
formed (Fig. 6c). Masson Trichrome staining identified
collagen synthesis (Fig. 6d) and Von Kussa staining re-
vealed the presence of matrix mineralization in newly
formed osteogenic tissue (Fig. 6e). HLA is the major histo-
compatibility complex (MHC) specific to humans. HLA-
ABC immunohistochemistry staining demonstrated that
the osteogenic tissue originated from human cells
(Fig. 6f).
iPMSCs were also seeded onto a PGA (Fig. 6g) scaffold
and cultured in adipogenic induction medium for 3
weeks. Induced cells adhered and proliferated on the
biocompatible porous PGA scaffold (Fig. 6h). Adipo-
genic fibroblast scaffold constructs were implanted sub-
cutaneously on the backs of nude mice for 2 months, at
which stage cell scaffold constructs were found to have
grown into adipose tissues in vivo. H & E staining re-
vealed lipid vacuoles while the undegraded PGA scaffold
remnants were found in the adipose tissue (Fig. 6i, j,
arrow). HLA-ABC immunohistochemistry staining also
confirmed that the adipogenic tissue originated from hu-
man cells (Fig. 6k).
Teratoma formation
Reprogrammed fibroblast cell suspensions (1 × 107 cells)
were mixed with matrigel and injected subcutaneously
into SCID mice without anesthesia. Teratoma formation
was observed after transplantation of iPMSCs subcuta-
neously on the backs of NOD/SCID mice for 2 months.
These teratomas contained tissues from all three germ
layers and included neural (ectoderm), epidermal (ecto-
derm), striated muscle (mesoderm), adipose (mesoderm),
and liver (endoderm) tissues, confirming the pluripo-
tency of the iPMSCs both in vitro and in vivo (Fig. 6l).
HLA-ABC immunohistochemistry staining confirmed
the teratomas were originated from human cells
(Fig. 6m). H & E staining shows the teratomas were
composed of tissues from three different germ layers
(Fig. 6n).
Discussion
Reprogramming of adult somatic cells into pluripotent
stem cells is believed to provide an attractive source of
stem cells for basic biological studies and regenerative
medicine. This has emerged as a potential method for
generating person-specific stem cells of any cell lineage,
bypassing the use of ESCs. Various methods are in use
Fig. 5 In-vitro neurogenic and pancreatic differentiation potential of induced stem cells. iPMSCs can be induced into neuron by defined media.
a Induced cells showed typical neuron morphology with soma, dendrites, and axons. GFAP, Nestin, MAP2, and β-Tubulin III marker proteins were
identified by immunofluorescence staining. b GFAP, Nestin, MAP2, and β-Tubulin III in protein expression in differentiated iPMSCs. c iPMSCs were
induced into islet cells. d Typical endocrine aggregates and expressed pancreatic specific markers such as Pdx1, glucagon and insulin are shown. Pdx1
was detected by anti-Pdx1 antibody whereas glucagon and insulin were stained. e Gene expression of Pdx1, glucagon, and insulin in induced cells
(pancreatic iPMSCs) and control group before induction (fibroblasts) (left panel). Note that total RNA was extracted from a mixed population of cells
with ~30 % displaying stem cell characteristics. *p < 0.01 between control IPMSCs before differentiation (fibroblasts) and after pancreatic conversion
(pancreatic induced IPMSCs). f Insulin secretion from induced pancreatic cells in response to various concentration of glucose. Bars represent an aver-
age of three reads. *p < 0.01 compared with 3.3 mM glucose induction. GFAP glial fibrillary acidic protein, IPMSC induced pluripotent mesenchymal
stem cell, MAP2 microtubule-associated protein 2, Pdx1 pancreatic and duodenal homeobox 1
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to generate iPSCs from somatic cells, most using gen-
ome integration by recombinant viral genomes that en-
code Yamanaka factors, transfection of nucleic acids
encoding Yamanaka factors, or introduction of small
molecule inducers of iPSCs.
Adult stem cells have been used over years in medi-
cine. MSCs have been evaluated for regenerative medi-
cine applications either through direct differentiation
into these tissues or indirectly through protein or cyto-
kine secretion. Patient-derived MSCs have been consid-
ered safe because they do not show tumor formation
after transplantation and are robust for various differen-
tiations. Concerns over the safety of viral-based tech-
nologies have motivated using nucleic acids and small
molecule-based technologies to produce autologous
stem cells for clinical therapy. However, even these ap-
proaches need further testing to determine whether sec-
ondary effects will undermine their safe use. Previous
use of purified transcription factor for generating iPSCs
was successful, although the efficiency of iPSC formation
was extremely low, limiting real-life applications. Here
we demonstrate improved reprogramming of somatic
cells using a different approach from previous method-
ologies [8, 9, 28]. Three key reprogramming factors
(Oct4, Sox2, and c-Myc) were expressed in Escherichia
coli as inclusion bodies, which were then solubilized,
refolded, and further purified in our studies. The fourth
reprogramming factor (Klf4) was expressed in HEK293
human cells and was soluble. Our process is therefore
capable of producing large quantities of purified recom-
binant reprogramming factors for clinical applications.
Indeed, various solubilization and refolding techniques
for processing inclusion body proteins to bioactive pro-
teins have been developed to allow facile and large-scale
production of therapeutic proteins [29].
The second improvement of our technology is the re-
programming factor packaging and delivery into the hu-
man cells. HVJ-E was originally developed as a vector
for the delivery of drugs and genes [30–32]. Furthermore,
HVJ-E has also been used for protein transduction to
investigate the function and character of proteins, such as
enzymes, cytokines, in vivo, or in cells [30, 33, 34]. We
found effective delivery by HVJ-E of packaged reprogram-
ming factors to human fibroblasts, with the majority of
cells showing positive staining for the exogenous trans-
ferred protein at a concentrations of (8 ~ 10) × 10-3 μg/ml.
We estimated an amount of 1 μg of each protein for
2 × 106 cells to make iPMSCs. Another major improve-
ment over small molecular and nucleic acid introduction
is the rapid turnover (>50 %) of the reprogramming
Fig. 6 In-vitro differentiation potential of iPMSCs. a β-TCP was used for in-vivo osteogenic differentiation. b Differentiated iPMSCs effectively
adhered to and proliferated on the scaffold. c H & E staining shows the structure of osteogenic tissue formed in vivo 2 months after implantation.
d Masson Trichrome staining shows the collagen fibers in the tissue. e Von Kussa staining confirms the presence of matrix mineralization. f HLA-ABC
immunohistochemistry staining confirmed the osteogenic tissue originated from human cells. g PGA was used for in-vivo adipogenic differentiation.
h Reprogrammed fibroblasts were seeded on a PGA scaffold and cultured in the adipogenic induction medium for 3 weeks. Induced fibroblasts
effectively adhered to and proliferated on the porous PGA scaffold. i H & E staining show the structure of adipogenic tissue formed in vivo 2 months
after implantation. j Lipid vacuoles were observed. Arrow indicates the undegraded PGA scaffold in vivo. k H & E staining for adipogenic tissue
originated from human cells. l HLA-ABC immunohistochemistry staining confirmed the adipogenic tissue originated from human cells. m HLA-ABC
immunohistochemistry staining of the teratomas confirmed it originated from human cells (① endoderm,② mesoderm,③ ecoderm). n Teratoma
formation from subcutaneous injection of iPMSCs into NOD/SCID mice. Tissues from endoderm, mesoderm, and ectoderm were formed in
the teratomas (shown by H & E staining,① endoderm,② mesoderm,③ ectoderm)
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factors, estimated to be 72 h post transduction, thus leav-
ing a limited biological footprint on the recipient cell. The
protein concentration we used was much lower than re-
ported previously, demonstrating higher efficiency [9]. We
also demonstrated that a HVJ-E-based packaging and de-
livery system can directly reprogram fibroblasts into dif-
ferent cell types such as osteoblasts, adipocytes, pancreatic
islets, and neural and teratoma cells.
During development and reprogramming, epigenetic
modifiers are thought to play a key role in ensuring the
correct patterns of DNA methylation and histone modifi-
cation for gene expression. Alteration of global epigenetic
marks occurs naturally during specific stages in the mam-
malian life cycle, and can also be artificially engineered
using a variety of reprogramming strategies. To validate
that HVJ-E packaged transcription factors did indeed alter
the epigenome we analyzed the differential methylation
between CD24+ and fibroblast cells. We observed gain of
methylation (hypermethylated DMRs) in low-to-medium
methylated regions concurrent with loss of methylation
(hypomethylated DMRs) in highly methylated regions.
These genes included gene sets that are regulated by
stem cell-related transcription factors (KLF1, MAPK8,
NANOG, SUZ12, SOX2, and MYC), confirming that
transduced recombinant transcription factors regulated
the programmed DNA methylation of stem cell-related
genes. As reported previously, we also found stem cell-
specific DMRs were significantly biased towards CpG
islands, suggesting that CpG islands containing genes have
a propensity to be differentially methylated during repro-
gramming towards pluripotent stem cells [35]. The higher
number of stem cell-specific DMRs in iPMSCs affecting
pluripotency gene expression indicates that the Yamanaka
factors only activate limited numbers of stem cell-specific/
associated genes through differential methylation com-
pared with the fibroblast genome.
Pluripotent cells derived by reprogramming fibroblast
cells could be further differentiated into different cell types.
Pluripotent stem cells produced with these recombinant
proteins were successfully differentiated into derivatives of
all three embryonic germ layers in vitro and in teratomas.
Reprogrammed iPMSCs could additionally form osteo-
genic and adipogenic tissues on scaffolds in vivo. During
our transgene-free iPSC reprogramming by protein factors
we observed a large number of cells to be positive for
CD105, a typical MSC marker, suggesting that the fibro-
blasts may have undergone quick derivation from iPSCs to
MSCs. MSCs derived from human iPSCs can be generated
in clonal expansion cultures and can be differentiated into
osteoblasts, adipocytes, and chondrocytes and promote
vascular and muscle regeneration. More detailed examin-
ation is needed to understand this phenomenon.
The field of cell reprogramming is expanding very
rapidly, and the tools for safer and more efficient
reprogramming have become increasingly important both
for basic research and for development of medical applica-
tions. Protein-based iPMSC technology offers a new and
potentially safer method for generating patient-specific
stem cells that does not require the destruction of ex-utero
embryos.
Conclusion
In summary, we describe a noninvasive, transgene-free,
protein-mediated approach to reprogramming somatic
cells. The reprogramming events led to epigenome alter-
ation and a specific phenotype. This approach eliminates
the potential risk associated with the use of viruses,
DNA transfection, and harmful chemicals. We anticipate
that protein-based reprogramming in future could pro-
vide a safe source of patient-specific cells for regenera-
tive medicine.
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Additional file 1: Figure S1. Showing isotype control for (A) anti-mouse,
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Acknowledgements
The authors would like to thank Dr Donald Comb, Dr Rich Roberts,
Dr William Jack, and Dr Clotilde Carlow at New England Biolabs Inc. for research
support and encouragement. They would also like to thank Dr Pierre-Olivier
Estève and Dr Chaithanya Ponnaluri for experimental suggestion and discussion.
Authors’ contributions
FC carried out the molecular biology, cell biology, and in-vivo experiments.
GZ carried out the NGS library construction and bioinformatics analysis.
LY and YF participated in the production of recombinant proteins and
generation of iPMSCs. XL, ZZ, and YW participated in the in-vitro differentiation
of iPMSCs and immunofluorescence assays. DS participated in the experiment
design and manuscript preparation. SP designed the experiments and drafted
the manuscript. All authors read, participated in drafting, critically revised, and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent
All experiments were conducted under the institutional ethical and safety
guidelines with approval by the Institutional Animal Care and Use Committee
and the Bioethics Committee of School of Biomedical Engineering Shanghai
Jiaotong University (approval reference number 2013011). All iPMSCs used in
this study are derived from the dermal fibroblast cells of healthy humans under
written consent previously approved by the Institutional Animal Care and Use
Committee and the Bioethics Committee of School of Biomedical Engineering
Shanghai Jiaotong University.
Chen et al. Stem Cell Research & Therapy  (2016) 7:99 Page 13 of 14
Author details
1Shanghai R&D Center, New England Biolabs, Shanghai 201203, China. 2New
England Biolabs, Ipswich, MA 01938, USA. 3Med-X Research Institute of
Shanghai Jiao Tong University, Shanghai 200030, China.
Received: 21 March 2016 Revised: 13 June 2016
Accepted: 29 June 2016
References
1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.
2. Yamanaka S. Strategies and new developments in the generation of
patient-specific pluripotent stem cells. Cell Stem Cell. 2007;1:39–49.
3. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced
pluripotent stem cells. Nature. 2007;448:313–7.
4. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C,
Brambrink T, Wu LC, Townes TM, et al. Treatment of sickle cell anemia mouse
model with iPS cells generated from autologous skin. Science. 2007;318:1920–3.
5. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Promotion of
direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci
U S A. 2010;107:14152–7.
6. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free
induction of pluripotency and subsequent excision of reprogramming
factors. Nature. 2009;458:771–5.
7. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hamalainen R, Cowling R,
Wang W, Liu P, Gertsenstein M, et al. piggyBac transposition reprograms
fibroblasts to induced pluripotent stem cells. Nature. 2009;458:766–70.
8. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA. Human
induced pluripotent stem cells free of vector and transgene sequences.
Science. 2009;324:797–801.
9. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y,
et al. Generation of induced pluripotent stem cells using recombinant proteins.
Cell Stem Cell. 2009;4:381–4.
10. Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY,
Lanza R, et al. Generation of human induced pluripotent stem cells by direct
delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472–6.
11. Zhang H, Ma Y, Gu J, Liao B, Li J, Wong J, Jin Y. Reprogramming of somatic
cells via TAT-mediated protein transduction of recombinant factors.
Biomaterials. 2012;33:5047–55.
12. Khan M, Narayanan K, Lu H, Choo Y, Du C, Wiradharma N, Yang YY, Wan AC.
Delivery of reprogramming factors into fibroblasts for generation of non-genetic
induced pluripotent stem cells using a cationic bolaamphiphile as a non-viral
vector. Biomaterials. 2013;34:5336–43.
13. Nemes C, Varga E, Polgar Z, Klincumhom N, Pirity MK, Dinnyes A.
Generation of mouse induced pluripotent stem cells by protein
transduction. Tissue Eng Part C Methods. 2014;20:383–92.
14. Li X, Zhang P, Wei C, Zhang Y. Generation of pluripotent stem cells via
protein transduction. Int J Dev Biol. 2014;58:21–7.
15. Sambrook J, Russell DW. Isolation of high-molecular-weight DNA from
mammalian cells using proteinase K and phenol. CSH Protoc. 2006;2006(1):
p.pdb.prot4036.
16. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for
Bisulfite-Seq applications. Bioinformatics. 2011;27:1571–2.
17. Hansen KD, Langmead B, Irizarry RA. BSmooth: from whole genome
bisulfite sequencing reads to differentially methylated regions. Genome Biol.
2012;13:R83.
18. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C,
Singh H, Glass CK. Simple combinations of lineage-determining
transcription factors prime cis-regulatory elements required for macrophage
and B cell identities. Mol Cell. 2010;38:576–89.
19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment
analysis: a knowledge-based approach for interpreting genome-wide
expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.
20. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P,
Franz M, Grouios C, Kazi F, Lopes CT, et al. The GeneMANIA prediction
server: biological network integration for gene prioritization and predicting
gene function. Nucleic Acids Res. 2010;38:W214–20.
21. Guo T, Hebrok M. Stem cells to pancreatic beta-cells: new sources for
diabetes cell therapy. Endocr Rev. 2009;30:214–27.
22. D'Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, Moorman MA,
Kroon E, Carpenter MK, Baetge EE. Production of pancreatic hormone-expressing
endocrine cells from human embryonic stem cells. Nat Biotechnol.
2006;24:1392–401.
23. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H,
Richardson M, Smart NG, Cunningham J, et al. Pancreatic endoderm derived
from human embryonic stem cells generates glucose-responsive insulin-secreting
cells in vivo. Nat Biotechnol. 2008;26:443–52.
24. Reinbothe TM, Safi F, Axelsson AS, Mollet IG, Rosengren AH. Optogenetic
control of insulin secretion in intact pancreatic islets with beta-cell-specific
expression of Channelrhodopsin-2. Islets. 2014;6, e28095.
25. Li JM, An JG, Wang X, Yan YB, Xiao E, He Y, Zhang Y. Imaging and histologic
features of traumatic temporomandibular joint ankylosis. Oral Surg Oral
Med Oral Pathol Oral Radiol. 2014;118:330–7.
26. Subbiah R, Du P, Van SY, Suhaeri M, Hwang MP, Lee K, Park K. Fibronectin-
tethered graphene oxide as an artificial matrix for osteogenesis. Biomed
Mater. 2014;9:065003.
27. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies
and beyond. Nat Rev Genet. 2012;13:484–92.
28. Zhou W, Freed CR. Adenoviral gene delivery can reprogram human
fibroblasts to induced pluripotent stem cells. Stem Cells. 2009;27:2667–74.
29. Lafevre-Bernt M, Wu S, Lin X. Recombinant, refolded tetrameric p53 and
gonadotropin-releasing hormone-p53 slow proliferation and induce
apoptosis in p53-deficient cancer cells. Mol Cancer Ther. 2008;7:1420–9.
30. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N,
Nakamura H, Morishita R, Kotani H. Hemagglutinating virus of Japan (HVJ)
envelope vector as a versatile gene delivery system. Mol Ther. 2002;6:219–26.
31. Kaneda Y. Applications of hemagglutinating virus of Japan in therapeutic
delivery systems. Expert Opin Drug Deliv. 2008;5:221–33.
32. Yasuoka E, Oshima K, Tamai K, Kubo T, Kaneda Y. Needleless intranasal
administration of HVJ-E containing allergen attenuates experimental allergic
rhinitis. J Mol Med (Berl). 2007;85:283–92.
33. Yuki S, Kondo Y, Kato F, Kato M, Matsuo N. Noncytotoxic ribonuclease,
RNase T1, induces tumor cell death via hemagglutinating virus of Japan
envelope vector. Eur J Biochem. 2004;271:3567–72.
34. Owada-Makabe K, Tsubota Y, Yukawa K, Kakimoto N, Liang XM, Ichinose M,
Maeda M. Direct in vivo protein transduction into a specific restricted brain
area in rats. Neurosci Lett. 2005;378:18–21.
35. Beck S, Lee BK, Rhee C, Song J, Woo AJ, Kim J. CpG island-mediated global
gene regulatory modes in mouse embryonic stem cells. Nat Commun.
2014;5:5490.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chen et al. Stem Cell Research & Therapy  (2016) 7:99 Page 14 of 14
